| Changcheng Zhu, MD | |
|
Mmc - Dept Of Pathology, 111 East 210th Street, Bronx, NY 10467 | |
| (718) 920-7866 | |
| Not Available |
| Full Name | Changcheng Zhu |
|---|---|
| Gender | Male |
| Speciality | Pathology |
| Experience | 40 Years |
| Location | Mmc - Dept Of Pathology, Bronx, New York |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1407936909 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207ZP0101X | Pathology - Anatomic Pathology | 234910 (New York) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Montefiore Medical Center | Bronx, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Montefiore Medical Center | 3779496021 | 2003 |
News Archive
Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs.
Advancements in sequencing and diagnostics technology are the underlying elements driving the genomic revolution. With the free-falling cost of sequencing, richer reference data and improved interpretation methods, the use of personal genomics is beginning to take greater root in clinical practice.
New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader AstraZeneca in what the company believes is a world-first commercial arrangement combining digital health technology with blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions.
Molecular Detection Inc. (MDI), a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application titled "Methods, Compositions and Kits for Detection and Analysis of Antibiotic Resistant Bacteria."
Research-clinicians at Children's National Health System have created a novel preclinical model that mimics the persistent interneuron loss seen in preterm human infants, identifying interneuron subtypes that could become future therapeutic targets to prevent or lessen neurodevelopmental risks, the team reports Jan. 31, 2019, in eNeuro.
› Verified 6 days ago
| Entity Name | Montefiore Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1063525152 PECOS PAC ID: 3779496021 Enrollment ID: O20031113000235 |
News Archive
Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs.
Advancements in sequencing and diagnostics technology are the underlying elements driving the genomic revolution. With the free-falling cost of sequencing, richer reference data and improved interpretation methods, the use of personal genomics is beginning to take greater root in clinical practice.
New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader AstraZeneca in what the company believes is a world-first commercial arrangement combining digital health technology with blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions.
Molecular Detection Inc. (MDI), a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application titled "Methods, Compositions and Kits for Detection and Analysis of Antibiotic Resistant Bacteria."
Research-clinicians at Children's National Health System have created a novel preclinical model that mimics the persistent interneuron loss seen in preterm human infants, identifying interneuron subtypes that could become future therapeutic targets to prevent or lessen neurodevelopmental risks, the team reports Jan. 31, 2019, in eNeuro.
› Verified 6 days ago
| Entity Name | Metropolitan Gastroenterology, Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528025756 PECOS PAC ID: 6406833722 Enrollment ID: O20040706000436 |
News Archive
Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs.
Advancements in sequencing and diagnostics technology are the underlying elements driving the genomic revolution. With the free-falling cost of sequencing, richer reference data and improved interpretation methods, the use of personal genomics is beginning to take greater root in clinical practice.
New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader AstraZeneca in what the company believes is a world-first commercial arrangement combining digital health technology with blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions.
Molecular Detection Inc. (MDI), a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application titled "Methods, Compositions and Kits for Detection and Analysis of Antibiotic Resistant Bacteria."
Research-clinicians at Children's National Health System have created a novel preclinical model that mimics the persistent interneuron loss seen in preterm human infants, identifying interneuron subtypes that could become future therapeutic targets to prevent or lessen neurodevelopmental risks, the team reports Jan. 31, 2019, in eNeuro.
› Verified 6 days ago
| Entity Name | Emanuel L. Kouroupos, M.d., P.c. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1457408163 PECOS PAC ID: 8123127933 Enrollment ID: O20070620000123 |
News Archive
Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs.
Advancements in sequencing and diagnostics technology are the underlying elements driving the genomic revolution. With the free-falling cost of sequencing, richer reference data and improved interpretation methods, the use of personal genomics is beginning to take greater root in clinical practice.
New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader AstraZeneca in what the company believes is a world-first commercial arrangement combining digital health technology with blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions.
Molecular Detection Inc. (MDI), a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application titled "Methods, Compositions and Kits for Detection and Analysis of Antibiotic Resistant Bacteria."
Research-clinicians at Children's National Health System have created a novel preclinical model that mimics the persistent interneuron loss seen in preterm human infants, identifying interneuron subtypes that could become future therapeutic targets to prevent or lessen neurodevelopmental risks, the team reports Jan. 31, 2019, in eNeuro.
› Verified 6 days ago
| Entity Name | Schwarz & Ammirati Medical Associates Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134200744 PECOS PAC ID: 1951292101 Enrollment ID: O20120112000158 |
News Archive
Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs.
Advancements in sequencing and diagnostics technology are the underlying elements driving the genomic revolution. With the free-falling cost of sequencing, richer reference data and improved interpretation methods, the use of personal genomics is beginning to take greater root in clinical practice.
New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader AstraZeneca in what the company believes is a world-first commercial arrangement combining digital health technology with blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions.
Molecular Detection Inc. (MDI), a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application titled "Methods, Compositions and Kits for Detection and Analysis of Antibiotic Resistant Bacteria."
Research-clinicians at Children's National Health System have created a novel preclinical model that mimics the persistent interneuron loss seen in preterm human infants, identifying interneuron subtypes that could become future therapeutic targets to prevent or lessen neurodevelopmental risks, the team reports Jan. 31, 2019, in eNeuro.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Changcheng Zhu, MD 329 S 42nd St, D8, Philadelphia, PA 19104-4062 Ph: () - | Changcheng Zhu, MD Mmc - Dept Of Pathology, 111 East 210th Street, Bronx, NY 10467 Ph: (718) 920-7866 |
News Archive
Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs.
Advancements in sequencing and diagnostics technology are the underlying elements driving the genomic revolution. With the free-falling cost of sequencing, richer reference data and improved interpretation methods, the use of personal genomics is beginning to take greater root in clinical practice.
New Zealand-based Adherium (NZ) Limited has entered a long term partnership with international pharmaceutical leader AstraZeneca in what the company believes is a world-first commercial arrangement combining digital health technology with blockbuster inhaler medications to improve health outcomes for patients with respiratory conditions.
Molecular Detection Inc. (MDI), a company developing Detect-Ready assays designed to increase the speed and accuracy of infectious disease diagnosis, today announced that it has received a notice of allowance from the US Patent and Trademark Office (USPTO) for a patent application titled "Methods, Compositions and Kits for Detection and Analysis of Antibiotic Resistant Bacteria."
Research-clinicians at Children's National Health System have created a novel preclinical model that mimics the persistent interneuron loss seen in preterm human infants, identifying interneuron subtypes that could become future therapeutic targets to prevent or lessen neurodevelopmental risks, the team reports Jan. 31, 2019, in eNeuro.
› Verified 6 days ago
Dr. Stephen Michael Factor, Pathology Medicare: Medicare Enrolled Practice Location: 1400 Pelham Pkwy S, Bronx, NY 10461 Phone: 718-918-3060 Fax: 718-918-4469 | |
Dr. Nichelle T Simmons, Pathology Medicare: Medicare Enrolled Practice Location: 1400 Pelham Pkwy S, Bronx, NY 10461 Phone: 718-918-3060 Fax: 718-918-4469 | |
Kathryn E Tanaka, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: 111 E 210th St, Surgical Pathology N-4, Bronx, NY 10467 Phone: 718-920-4976 Fax: 718-920-7611 | |
Dr. Mark Everett Smethurst, M.D. Pathology Medicare: Accepting Medicare Assignments Practice Location: 130 W Kingsbridge Rd, Bronx, NY 10468 Phone: 718-584-9000 Fax: 718-741-4615 | |
Kathie Schlesinger, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: Mmc - Dept. Of Pathology, 111 East 210th Street, Bronx, NY 10467 Phone: 718-920-6329 | |
Sandra E Reznik, MD Pathology Medicare: Not Enrolled in Medicare Practice Location: Weiler - Dept. Of Pathology, 1825 Eastchester Road, 3rd Fl., Bronx, NY 10461 Phone: 718-904-2861 | |
Dr. Adam Jay Gersten, MD Pathology Medicare: May Accept Medicare Assignments Practice Location: 111 E 210th St, Foreman 4 - Department Of Pathology, Bronx, NY 10467 Phone: 718-920-4976 |